Did Biogen's Kingsley Take Blame For Tecfidera Sales?
This article was originally published in Scrip
The timing of Biogen's Oct. 9 announcement that Tony Kingsley, executive vice president of global commercial operations, is leaving the company came at an unfortunate time – just weeks before third quarter earnings will reveal whether Tecfidera (dimethyl fumarate) sales are growing, stable or sliding.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.